We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2021 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that China has conditionally approved Orpathys for patients with non-small cell lung cancer and mesenchymal-to-epithelial transition gene alterations.
The pharmaceutical company said that continued approval is contingent upon the successful completion of a confirmatory trial, and that it was based on positive results from a Phase 2 trial conducted in the country.
"Orpathys demonstrated robust anti-tumor activity based on an independent review of objective response rate in the trial's primary endpoint and its disease control rate," the company said.
AstraZeneca said the approval of Orpathys follows a priority review designation by China's Center for Drug Evaluation of the National Medical Products Administration, and represents the first global regulatory approval for the MET tyrosine kinase inhibitor.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 23, 2021 02:36 ET (06:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
